Regeneron Pharmaceuticals Inc

More Details of Regeneron Pharmaceuticals Inc Company

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.

Company Info

Ticker SymbolREGN

Company nameRegeneron Pharmaceuticals Inc

IPO dateApr 02, 1991

CEODr. Leonard S. Schleifer, M.D., Ph.D

Number of employees15106

Security typeOrdinary Share

Fiscal year-endApr 02

Address777 Old Saw Mill River Road

CityTARRYTOWN

Stock exchangeNASDAQ Global Select Consolidated

CountryUnited States of America

Postal code10591

Phone17813705000

Websitehttps://www.regeneron.com/

Ticker SymbolREGN

IPO dateApr 02, 1991

CEODr. Leonard S. Schleifer, M.D., Ph.D

Company Executives

Name

Name/Position

Position

Shareholding

Change

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.11M

+42.02%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

670.48K

-3.59%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

53.42K

+0.05%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.92K

+0.07%

Mr. George L. Sing

Independent Director

29.89K

-0.06%

Mr. Christopher R. Fenimore

Chief Financial Officer, Executive Vice President - Finance

19.75K

+20.78%

Mr. Arthur F. (Art) Ryan

Independent Director

17.66K

-0.10%

Ms. Marion E. McCourt

Executive Vice President - Commercial

14.37K

+9.94%

Dr. Michael S. Brown, M.D.

Independent Director

12.62K

-0.13%

Name

Name/Position

Position

Shareholding

Change

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.11M

+42.02%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

670.48K

-3.59%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

53.42K

+0.05%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.92K

+0.07%

Mr. George L. Sing

Independent Director

29.89K

-0.06%

Revenue Breakdown

Currency: USDUpdated: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

Sanofi

1.18B

39.07%

EYLEA

736.00M

24.30%

Bayer

343.90M

11.35%

EYLEA HD

306.80M

10.13%

Libtayo

192.50M

6.36%

Other

266.30M

8.79%

No Data

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Sanofi

1.18B

39.07%

EYLEA

736.00M

24.30%

Bayer

343.90M

11.35%

EYLEA HD

306.80M

10.13%

Libtayo

192.50M

6.36%

Other

266.30M

8.79%

Shareholding Stats

Updated: Sat, Aug 30

Shareholders

Shareholder Types

Shareholders

Proportion

The Vanguard Group, Inc.

9.00%

BlackRock Institutional Trust Company, N.A.

5.44%

State Street Global Advisors (US)

4.64%

Dodge & Cox

3.67%

Fidelity Management & Research Company LLC

3.13%

Other

74.12%

Shareholders

Proportion

The Vanguard Group, Inc.

9.00%

BlackRock Institutional Trust Company, N.A.

5.44%

State Street Global Advisors (US)

4.64%

Dodge & Cox

3.67%

Fidelity Management & Research Company LLC

3.13%

Other

74.12%

Shareholder Types

Shareholders

Proportion

Investment Advisor

47.67%

Investment Advisor/Hedge Fund

28.51%

Hedge Fund

5.34%

Research Firm

2.70%

Pension Fund

2.54%

Bank and Trust

2.15%

Individual Investor

2.01%

Sovereign Wealth Fund

1.22%

Insurance Company

0.08%

Other

7.78%

Institutional Shareholding

Updated: Tue, Jul 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q2

2585

99.72M

95.69%

-2.03M

2025Q1

2621

99.84M

93.97%

-1.42M

2024Q4

2581

100.17M

93.15%

-475.65K

2024Q3

2505

99.81M

90.67%

-1.99M

2024Q2

2479

100.87M

93.10%

+570.24K

2024Q1

2440

99.77M

92.44%

+388.23K

2023Q4

2406

98.50M

91.94%

-617.06K

2023Q3

2358

98.79M

92.52%

-1.71M

2023Q2

2360

99.25M

92.00%

-1.42M

2023Q1

2366

99.66M

92.70%

-1.10M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

9.36M

8.81%

+117.55K

+1.27%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

5.74M

5.41%

+45.93K

+0.81%

Mar 31, 2025

State Street Global Advisors (US)

4.79M

4.51%

-42.58K

-0.88%

Mar 31, 2025

Dodge & Cox

2.32M

2.19%

+2.77K

+0.12%

Mar 31, 2025

Fidelity Management & Research Company LLC

7.40M

6.97%

-573.19K

-7.19%

Mar 31, 2025

Capital International Investors

3.99M

3.76%

-747.80K

-15.79%

Mar 31, 2025

JP Morgan Asset Management

4.08M

3.84%

-1.16M

-22.19%

Mar 31, 2025

Geode Capital Management, L.L.C.

2.47M

2.33%

+41.95K

+1.73%

Mar 31, 2025

Invesco Capital Management (QQQ Trust)

2.19M

2.07%

-36.81K

-1.65%

Jun 30, 2025

Putnam Investment Management, L.L.C.

1.91M

1.8%

+285.04K

+17.50%

Mar 31, 2025

Related ETFs

Updated: Sat, Sep 6

Name

Proportion

Amplify Weight Loss Drug & Treatment ETF

7.43%

Simplify Health Care ETF

7.25%

Invesco Nasdaq Biotechnology ETF

6.57%

ProShares Ultra Nasdaq Biotechnology

6.13%

iShares Biotechnology ETF

5.83%

VanEck Biotech ETF

5.37%

iShares Genomics Immunology and Healthcare ETF

4.74%

First Trust NYSE Arca Biotechnology Index Fund

3.43%

First Trust NASDAQ Pharmaceuticals ETF

3.36%

iShares US Tech Breakthrough Multisector ETF

2.99%

Amplify Weight Loss Drug & Treatment ETF

Proportion7.43%

Simplify Health Care ETF

Proportion7.25%

Invesco Nasdaq Biotechnology ETF

Proportion6.57%

ProShares Ultra Nasdaq Biotechnology

Proportion6.13%

iShares Biotechnology ETF

Proportion5.83%

VanEck Biotech ETF

Proportion5.37%

iShares Genomics Immunology and Healthcare ETF

Proportion4.74%

First Trust NYSE Arca Biotechnology Index Fund

Proportion3.43%

First Trust NASDAQ Pharmaceuticals ETF

Proportion3.36%

iShares US Tech Breakthrough Multisector ETF

Proportion2.99%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

Feb 04, 2025

REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025

Feb 20, 2025

Mar 20, 2025

Feb 20, 2025

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

575.060USD

Regeneron Pharmaceuticals Inc

575.060

Overview

Company

Financials

Analysis